A digital pharma day: innovation comes to town

Posted 7th October 2011 in Articles, Commercial | Register to comment

As the conference season hits full swing again, Paul Tunnah gets out and about to see who’s innovating and who’s winning in the world of digital pharma.

Last week I found myself attending not one, but two digital pharma events, which provided an excellent opportunity to check the pulse of the industry…

What makes GSK the number one pharmaceutical company in Egypt?

Posted 6th October 2011 in Articles, Commercial | Register to comment

Nader Rizkalla investigates why GSK is doing so well in Egypt, elaborating on the key success factors in this emerging, but critical, North African market.

GSK has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at…

Off-label use in Australia and relevant considerations

Posted 5th October 2011 in Articles, Commercial | Register to comment

Whilst off-label use remains a grey area in regulatory terms Mabel Tsui highlights the lessons that Australia can learn from the US in this area.

With the growth of off-label use there is now increasing enthusiasm in how pharmaceutical companies will promote their products to health providers for…

Comparative effectiveness evidence: Comparing apples and oranges?

Posted 4th October 2011 in Articles, General | 1 comment

Pharmaceutical companies face increasing demands for effectiveness evidence, and thus escalating costs. Here Jeanni van Loon describes a mean to generate evidence without the need for additional trials.

Development plans typically identify comparators that will meet regulatory needs and go some way to meeting the needs of other…

Middle management: is sheer will enough to get them through?

Posted 3rd October 2011 in Articles, General | Register to comment

Jane Chin highlights the challenges faced by middle management and the impact it has on the company.

If you are what today’s pharmaceutical middle managers face in “Tales from the Middle”, you may wonder why anyone would aspire to enter…

Editor’s voice – September 2011

Posted 30th September 2011 in Articles, General | Register to comment

As another month draws to a close Rebecca Aris reflects on the highlights of pharmaphorum from September and reviews what’s coming up in October.

September has been another busy month for us as we continue to publish daily, keep the content varied and sneak out of the office to attend events when…

Patient perspectives: Kelly Young

Posted 29th September 2011 in Articles | Register to comment

In the second of our patient perspectives series we speak with Kelly Young, also known as ‘RA warrior’.

Kelly Young has bravely battled with chronic autoimmune illness most of her life. At 13, began the onset of her Rheumatoid Arthritis …

Patent expiry & social media: a pharma story of biblical significance

Posted 29th September 2011 in Articles, General | Register to comment

Richard Heale highlights the link between patent expiration in pharma and social media.

In the beginning Pharma created its ‘block-buster’ fatted calves.

Protected by aging patents they will over the next six years put US$267 billion of revenue at risk through patent expiry…

Rare is different: patients and caregivers are key drivers of diagnosis and treatment in rare diseases

Posted 28th September 2011 in Articles, General | Register to comment

In part three of the ‘Rare is different’ series, Katie Mihelich shares some powerful experiences of rare disease patients and caregivers, and explains why it’s important for pharma marketers to acknowledge their elevated level of empowerment.

Fifty percent of rare disease patients are children and 80 percent of rare disease patients are diagnosed during…

Five things you didn’t know about off-label sales compliance

Posted 27th September 2011 in Articles, General | Register to comment

Maureen Shaffer shares her tips on off-label sales compliance.

Off-label sales compliance is difficult. There is subtlety to staying on message. Pharma sales representatives are highly mobile and verbal. Compliance and…